To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Clinical trial NCT06192849 · RECRUITING
Trial details
- NCT number
- NCT06192849
- Sponsor
- Juan LI, MD
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-31
- Primary completion
- 2026-12-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.